2023 Congress Leadership

Dr. Balch has more than 20 years of executive leadership in the non-profit sector with an emphasis on consensus-building and collaboration. He became the CEO of both PAF and NPAF in 2013. From 2006-2013, he served as Vice President of the Preventive Health Partnership -- a national health promotion collaboration between the American Cancer Society, American Diabetes Association, and American Heart Association. Prior to his work with the Preventive Health Partnership, Dr. Balch was the Executive Director of Friends of Cancer Research.  

In May of 2022, Dr. Balch was named Co-Chair of the ISPOR Patient Representatives Roundtable for North America. He volunteers as a board member for the Council for Affordable Health Coverage (CAHC), Innovation and Value Initiative (IVI), Specialty Pharmacy Certification Board (SPCB)) and the Foundation for the Accreditation of Cellular Therapy (FACT) and recently completed his term as a board member for the Pharmacy Quality Alliance (PQA). Dr. Balch has served on the Executive Board of Patient Advocate Foundation and National Patient Advocate Foundation since 2007.  From 2006 to 2016, Dr. Balch served on the board of Fight Colorectal Cancer including several years as Vice Chair.  

Dr. Balch also serves on numerous advisory boards and committees including the National Committee for Quality Assurance (NCQA) Consumer Advisory Council; Duke-Margolis Value-Based Payment Advisory Board; Hutchinson Institute for Cancer Outcomes Research (HICOR) Advisory Board and the Journal of Clinical Pathways Editorial Advisory Board and contributing editor. 

He earned his PhD in 2003 from the University of California, his master’s degree in 1997 from the University of Texas; and his bachelor’s degree (cum laude) in 1994 from Trinity University in San Antonio.

Carla Balch is a tenured healthcare executive with expertise in building infrastructure and enterprise growth in the healthcare technology market sector. As Founder and Chief Executive Officer of Spesana, her motivation to create ground-breaking technology products and innovative market strategies is rooted in the belief every patient deserves the best care available. Ms. Balch realized her passion for patient care technology solutions as Director of Product Development and Senior Financial Operations Manager of SOS/ACORN, an oncology research firm and community research network formed by the West Cancer Center, Memphis.

Prior to founding Spesana, Ms. Balch served as President of Nantcare, a California-based oncology clinical trials and technology company. Further, as President and Chief Executive Officer of Altos Solutions, the first web-based oncology electronic medical record and big data company, Ms. Balch led its acquisition by to Flatiron Health, a Google-Ventures backed organization that was subsequently acquired by Roche.

A graduate of University of Memphis with a cum laude Master of Science in Psychology, Ms. Balch holds patents for machine vision and molecular diagnostic interpretation and serves as a Healthcare Board Member of the Federal Reserve Bank in St. Louis, Missouri, and serves on the Board of Directors of Florence Healthcare.

Mr. Barkley is a healthcare business advisor specializing in the transaction of physician and hospital business relationships, particularly consolidated oncology service lines and cancer centers and in value-based care and alternative payment models in oncology. Mr. Barkley is the President of the Cancer Center Business Development Group.

Mr. Barkley served as Executive Director of New Hampshire Hematology Oncology, a regional oncology medical group practice and during his tenure, developed an innovative business model relationship between the practice and Dana Farber Cancer Institute, Boston. He also served as Regional Market Executive for the Chicago-area practices of the McKesson/US Oncology Network and as professional business advisor in oncology practice mergers, acquisitions and oncologist-hospital affiliations in numerous market settings nationally.

Mr. Barkley holds a Master’s Degree in Healthcare Administration and a Law Degree with emphasis in healthcare transactional and regulatory law. He is a member of the State Bar of California; American Health Lawyer’s Association (AHLA) and the Association of Community Cancer Centers (ACCC) and is a Founding Member of the Cancer Business Forum. 

Alexis Bortniker is a health care transactional lawyer in the San Diego office of Foley & Lardner LLP and is chair of the firm’s health care transaction group. Ms. Bortniker is a strategic advisor, working with health care providers, payers, private equity companies, and technology companies on joint ventures, mergers and acquisitions, payment structures, and complex business transactions. Ms. Bortniker has extensive experience in alternative payment models, population health management, risk-based reimbursement systems, and payer/provider alignment. She has significant experience working with providers in Medicare Advantage and CMMI demonstration models. Ms. Bortniker also advises emerging companies in navigating the move away from direct-to-consumer payment models to third party payment strategies, including commercial payment, direct to employer, centers of excellence and more.

She also has considerable experience in matters involving fraud and abuse compliance, including self-referral and anti-kickback laws, Medicare and Medicaid reimbursement, self-disclosures and overpayments. This experience allows her to provide full-service transactional guidance to health care entities in their transactions. Ms. Bortniker also works regularly with oncology practices, advising on a variety of developing legal areas, including risk and outcomes-based payment models and joint ventures.

Nina Chavez is Vice President of Customer Experience at Flatiron Health. Ms. Chavez leads the Flatiron Healthcare (HC) community oncology customer experience from go-live onward, encompassing the Account Management, Implementation, Optimization and the Strategic Partnerships teams. She is a subject matter expert in value-based care and clinical practice transformation. 

Ms. Chavez joined Flatiron in 2020 with 16 years of practice experience at the New Mexico Cancer Center (NMCC). In her previous role as Chief Operating Officer at NMCC, she served on the boards of the Association of Community Cancer Centers and the Coalition of Hematology and Oncology Practices. Additionally, she is a fellow with the American College of Medical Practice Executives.

Rushir J. Choksi, MD, is a medical oncologist in Butler, Pennsylvania and is affiliated with multiple hospitals in the area, including UPMC Horizon and UPMC Presbyterian Shadyside. Dr. Choksi sees all medical oncology and hematology cases. 

Dr. Choksi is board-certified in internal medicine, medical oncology, and hematology, and received his medical degree from Wake Forest University School of Medicine in Winston-Salem, NC. Dr. Choksi completed both his internal medicine residency and hematology/oncology fellowship at UPMC. 

Dr. Choksi is a member of the American Society of Clinical Oncology and the American Society of Hematology.

Dr. Edge is VP of System Quality and Professor of Oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY. He is the Medical Director of the Clinical Oncology Pathways Program. His research interests are in health outcomes and quality care and breast cancer care. He is on the Board of the NCCN and the Executive Committee of the American Joint Committee on Cancer. He is a past member of the Board of ASCO, past Chair of the Commission on Cancer, and past Editor-in-Chief of the AJCC Cancer Staging Manual. He served on the ASCO Pathways Taskforce.

Dr. Hamrick leads a team of physicians, nurses, and informatics specialists who inform the development and applications of the Flatiron HC products and services relied upon by front-line clinicians in hundreds of cancer clinics across the United States. 

Dr. Hamrick also maintains a clinical practice part-time at Kaiser Permanente of Georgia in Atlanta, where he previously served as chief of medical oncology and hematology and was in the private practice of oncology and hematology at Georgia Cancer Specialists. He is on the board of the Georgia Center for Oncology Research and Education and previously served on the Kaiser Permanente National Inter-Regional Cancer Leadership Council and the KP National Cancer Chiefs Council. 

Dr. Hamrick received his MD and an MPH in epidemiology from the University of North Carolina at Chapel Hill. He completed his residency and hematology/oncology fellowship at the University of California San Francisco. He is board-certified in internal medicine, medical oncology, and hematology.

Mr. Hennessy is Principal at Valuate Health Consultancy. Valuate helps people get access to the health care they need by guiding manufacturers in value-strategy optimization and commercialization. Mr. Hennessy has been engaged in the delivery of oncology care for more than 20 years with experience in physician practice as well as hospital service lines, in community and academic settings. He served as the Vice President of Health Affairs for Sarah Cannon Cancer Services, a division of Hospital Corporation of America (HCA) focusing on best practices and operational excellence and health reform efforts in oncology and the broader healthcare arena. He was also responsible for the collaboration of physicians, leadership teams, and staff in several HCA oncology markets. 

Mr. Hennessy served as the Executive Director of Kansas City Cancer Centers, a US Oncology Network Practice Affiliate, as well as the Executive Director for the Community Cancer Program of the University of Kansas Medical Center. Further, Mr. Hennessy has extensive experience in managed care strategies from both the payor and provider perspectives, including provider network product redesign in the worker’s compensation environment. 

Mr. Hennessy is a member and Ambassador of the American Society of Clinical Oncology (ASCO) and serves on several committees including the Clinical Practice Committee and the Education Committee. John served on the Payment Reform Task Force that developed ASCO’s Patient-Centered Oncology Payment (P-COP) alternative payment model. He is the Vice President of the Board of Directors of the Young Survival Coalition has formerly served on the Board of Trustees of the Association of Community Cancer Centers and as Executive Director of the Kansas Society of Clinical Oncology. John has co-authored manuscripts published in ASCO’s Journal of Clinical Oncology Practice (JCOP), as well as the Journal of Clinical Ethics. John holds a Master’s Degree in Business Administration from the Fuqua School of Business at Duke University.

Dr. Hertler, as the Chief Medical Officer of New Century Health, is responsible for the advancement of the company’s clinical quality initiatives, value-based strategies and utilization management policies and operations. A board-certified oncologist who left clinical practice in 2014, he is a nationally recognized leader in oncology clinical practice. Dr. Hertler was a past member of several American Society of Clinical Oncology committees, including the Clinical Practice, Quality of Care and Payment Reform Committees. 

Prior to joining the New Century Health in 2014, Dr. Hertler was the Administrative Medical Director for Physician Practices at Maine General Medical Center and the Medical Director of the Harold Alfond Center for Cancer Care in Augusta, Maine. He is a past president of the Northern New England Clinical Oncology Society. Earlier in his career, Dr. Hertler was Assistant Professor of Medicine in Hematology/Oncology at the Louisiana State University Medical School. 

Dr. Hertler received his medical degree from the University of Michigan and completed his residency in Internal Medicine at University of Michigan affiliated hospitals. He later completed a Fellowship in Medical Oncology/Hematology at Duke University Medical Center. He received his bachelor’s degree in chemistry with highest honors from Dartmouth College.

Manasi Kapoor is a Market Insights Manager in Memorial Sloan Kettering’s Office of Technology Development. She works on the Digital Health team of OTD’s Technology Management and Commercialization unit. 

Before joining MSK in 2021, Ms. Kapoor was a Managing Director at OptumInsight, serving biotech and pharma clients. Her previous roles include working as a Strategic Consultant with Gartner; as a Senior Consultant at The Advisory Board Company, where she advised senior health system executives on a variety of strategic and operational issues. Ms. Kapoor received an MBA degree from Georgetown University, McDonough School of Business, and a BA degree in Economics and Political Science from Macalester College.

Dr. Ira Klein is the Vice President of Medical Affairs for Payor Relations for Tempus, a data driven precision medicine company in the cancer genomics, and pharmacogenomics space.  Prior to this new position, he was the Chief Medical Officer of Health New England, leading plans efforts in medical management, contracting, network integrity, and quality and analytics.  Previously, he was the leader and Senior Director of Healthcare Quality Strategy in J&J Health Care Services for 5 years, building a new quality strategy capability for the Janssen brands.  In 10 years at Aetna, he was the National Medical Director for Clinical Thought Leadership, Chief of Staff to the CMO, founded the Oncology Solutions team that created pathways and medical home value based arrangements; also developed novel wellness and benefit design programs in the large employer segment of Aetna's National Accounts business.  His early career included Assistant CMO of Bayshore Community Health Systems for 3 years, working in all aspects of inpatient and outpatient business, CMO of Elderplan for 2 years, serving the frail elderly in NYC, and practicing Internal Medicine for 7 years at Robert Wood Johnson Medical School as Assistant Professor in Internal Medicine.   

Dr. Klein is an AOA graduate of Robert Wood Johnson Medical School, and completed residency training at Brown University and RWJMS/UMDNJ, as well as an MBA from Rutgers School of Business, and remains board certified in Internal Medicine.  He has a personal interest in health information technology and data security, previously certified in the medical HIT area.

Wui-Jin Koh, MD, is the Senior Vice President/Chief Medical Officer at the National Comprehensive Cancer Network (NCCN). In this role, he helps oversee the flagship NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) program. In addition, he is responsible for medical leadership and oversight for NCCN’s continuing medical education program and JNCCN — Journal of the National Comprehensive Cancer Network, and represents the organization at clinical and scientific meetings. He is also actively involved in the NCCN Global initiatives. 

Prior to joining NCCN in 2018, he served as Professor of Radiation Oncology at University of Washington and Medical Director for Radiation Oncology at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance. 

Dr. Koh earned his medical degree at Loma Linda University School of Medicine. He conducted his post-graduate training at the University of Washington Medical Center, completing a residency in radiation oncology and a clinical fellowship in metabolic tumor imaging. He is board-certified in radiation oncology.  

Dr. Koh’s research interests include combined chemo-radiation strategies, cancer management guidelines development, and the role of imaging in radiotherapy and cancer care. He specialized in the management of gynecologic and gastrointestinal tract tumors and the use of brachytherapy and intraoperative radiotherapy. He has received multiple Educator and National Top Doctors awards. 

Dr. Koh is well-published and involved in numerous professional societies, including the Society of Gynecologic Oncology, the American Society of Clinical Oncology, the NRG-Oncology Clinical Trials Cooperative Group, the Western Association of Gynecologic Oncology, and the International Gynecologic Cancer Society.

Michael Kolodziej M.D. is Senior Advisor, ADVI Health. Dr. Kolodziej attended medical school at Washington University in St. Louis and did his Internal Medicine residency and Hematology-Oncology fellowship at the University of Pennsylvania. He was an associate professor at the University of Oklahoma from 1991-98. He practiced oncology with New York Oncology from 1998-2013.  During this time, he also was chairman of the US Oncology Pharmacy and Therapeutics committee. In this role, he helped direct the implementation of the USON clinical pathways initiative. He joined Aetna in January, 2013 as National Medical Director, Oncology Solutions. While at Aetna, he directed Aetna’s oncology programs and was the architect of the Aetna Oncology Medical Home. Dr. Kolodziej joined Flatiron Health in July, 2016 as National Medical Director, Managed Care Strategy. He joined ADVI in October, 2017. He is a Fellow of the American College of Physicians. He serves as head of medical oncology at Canopy Oncology.

Dr. Levine is President of Health Innovation and Policy for City of Hope, an NCI-designated comprehensive cancer center. He also serves as the Chairman of the Board of AccessHope, a company spun out from City of Hope that is focused on serving the employer market and making leading-edge cancer care available to all regardless of geographical location.  

Prior to City of Hope, Dr. Levine held executive roles at UnitedHealth Group, Towers Watson and Anthem Inc. He currently serves as a Board Member of a number of healthcare organizations, including BioScienceLA; Keck Graduate Institute; Vida Health; Active Life Scientific and Reimagine Care. In addition, Dr. Levine is a member of the Accessibility and Affordability Working Group for California Institute for Regenerative Medicine, a senior fellow for Health Evolution Forum’s New Models of Care Delivery and a long-term strategic advisor to the founder/chairman of the board of Quantum Health.  

Dr. Levine is certified by the American Board of Internal Medicine and licensed by the Medical Board of California. He earned his undergraduate degree from Harvard College and his medical degree from the University of California San Francisco. He interned at Mount Zion Hospital and Medical Center in San Francisco and completed his residency in internal medicine at Cedars-Sinai Health System in Los Angeles.

Barbara L. McAneny, MD, a board-certified medical oncologist/hematologist from Albuquerque, N.M., became the 173rd president of the AMA. She has been a member of the AMA Board of Trustees and served as chair. She is a fellow and former member of the board of the American Society of Clinical Oncology (ASCO), a master of the American College of Physicians, and past president of NM Medical Society (NMMS) and the Greater Albuquerque Medical Association. She served on the Community Oncology Alliance Board of Trustees and is one of the founders and current chair of the National Cancer Care Alliance, a group of independent practices collaborating to deliver high-quality, cancer care with alternative payment models based on data-driven principles. Dr. McAneny’s interest in using data to improve practice sustainability began when she was appointed to the Centers for Medicare & Medicaid Service’s Practicing Physicians Advisory Council. She received a $19.8 million grant from Centers for Medicare & Medicaid Innovation to show how oncology practices could use triage pathways to lower costs, named COME HOME (Community Oncology Medical Home), later incorporated into Medicare’s Oncology Care Model. She co-founded NM Oncology Hematology Consultants Ltd in 1987 and built NM Cancer Center as the first physician-owned multi-disciplinary cancer center in the state. Dr. McAneny graduated magna cum laude from the University of Minnesota and with honors from University of Iowa College of Medicine, completing her residency in internal medicine at the University of Iowa and fellowship in hematology/oncology at the University of New Mexico.

Mr. Mounce is the Chief Executive Officer of Oncology Care Partners (OCP), a transformative provider organization in cancer care designed to provide care exclusively to patients within value-based contracts, Medicare Advantage Plans for example. OCP is focused on disrupting the fee for service status quo in oncology care. 

Mr. Mounce has over 40 years healthcare experience with a unique mix of operational leadership for physician-led care models, ambulatory care delivery settings, and acute care hospital systems. Mr. Mounce served as the Chief Operating officer of OneOncology, a national network of 15 high-value oncology medical group practices. Prior to OneOncology, he served as the Chief Executive Officer of The West Clinic / West Cancer Center, one of the nation’s top community oncology practices. During his tenure with OneOncology and West Cancer Center, he gained a national recognition for private practice innovation and development of collaborative multidisciplinary operating models with partnerships, such as hospital systems, payers, and participation in early value-based oncology care models. 

Prior to his experience in the oncology sector, Mr. Mounce served in a variety of C-suite roles for an acute care hospital company and a physician owned Medicare Advantage plan. Mr. Mounce began his healthcare career with the Los Angeles City Fire Department where he proudly served in the field for a decade as a Senior Fire Paramedic.

For the past two decades, Mr. Rodgers has been a visionary for the creation and evolution of oncology clinical pathways. He is a strong believer in their utility in improving outcomes for patients with cancer. Mr. Rodgers currently serves as Director of Network Development for Elsevier’s ClinicalPath, leading a team that provides oncology pathway solutions to provider practices of all sizes and site of service. 

Prior to his current role leading the network development efforts, Mr. Rodgers was the founding software engineer for Via Oncology (which has become ClinicalPath). He has deep knowledge of healthcare information technologies, analytics, and the root-cause limitations of both. He is a strong patient advocate, believing that patient quality of life, however that patient defines “quality of life”, should remain the principal goal of care. Mr. Rodgers received his Bachelors of Science degree from the University of Pittsburgh in Natural Sciences.

Mr. Russo is the Chief Executive Officer of The Center for Cancer and Blood Disorders, an independent medical group community practice based in Dallas/Fort Worth. The Center is a member of OneOncology, a national network of fifteen high-value oncology medical group practices. Mr. Russo has over 30 years of healthcare experience including academic medical center, community practice and community hospital settings. 

Mr. Russo serves as a Member of the Board of Directors of Community Oncology Alliance (COA) and is a member of the Association of Community Cancer Centers (ACCC), American Society of Clinical Oncology (ASCO) and the Texas Medical Group Management Association (TXMGMA). He holds an MBA from the University of Dallas and resides in Colleyville, Texas. Mr. Russo is a Founding Member of the Cancer Business Forum.

Dr. Saulet is passionate about changing how we pay for and deliver cancer care. In her role as Market Vice President of Oncology at Carrum Health, she oversees the Cancer Centers of Excellence program, which connects self-insured employers to high-value cancer care providers. 

Prior to Carrum, Dr. Saulet spent ten years at Advisory Board (an independent subsidiary of Optum), where she served as Expert Partner, Practice Manager, and Consultant for the Oncology Roundtable. She managed client relationships and led research on oncology trends and best practices in payment reform, patient experience, and clinical innovations. She received her Bachelors of Science from the College of William & Mary and her PhD in Immunology from Duke University. Dr. Saulet is a Founding Member of the Cancer Business Forum. 

I was born and raised in Greater Cleveland, Ohio, graduated Magna Cum Laude from Holy Cross College, and graduated AOA from Case Western Reserve School of Medicine. My Internal Medicine Residency, as well as my Fellowship in Medical Oncology/Hematology at Emory University Affiliated Hospitals concluded in 1983. I co-founded and worked in clinical practice at Central Georgia Cancer Care until 2018. I remain on the Academic Faculty at Mercer University School of Medicine in the Department of Internal Medicine, and I have served as the Founding Board of Director's Chair with the Georgia Center for Research and Education & Research. 

I am a member of ASCO, serving as a member of the Clinical Practice Committee for a term, and later rewarded an ASCO award for excellence in clinical research as an ECOG investigator in 2003. I was a founding member of the Community Oncology Alliance (COA) in 2003 and served as it's President in 2006. Beginning in 2018, I accepted the Chief Medical Officer position at COA and am currently working with COA to foster a broad quality and value-based initiative under the aegis of the National Cancer Treatment Alliance (NCTA). Finally, my interest in pathways arose during the creation and implementation of Evidence-based Treatment Pathways with the Cancer Clinics of Excellence (CCE), as a member of the Board of Directors, as well as the CCE Chief Clinical Officer, from a period of time extending from 2007-2015.

With more than 30 years of healthcare experience Mr. Schonherz serves AON as Chief Executive Officer and is a Board Member on the Board of Managers. Mr. Schonherz is responsible for overseeing AON’s mission, strategy, operations and finances. As President & Chief Operating Officer of AON since its inception in 2017 to 2021, he made significant contributions across practice operations, central ancillaries, information technology and strategy. 

In his role as Florida Cancer Specialists (FCS) Chief Operating Officer, he was responsible for the day-to-day operations within the corporate office and nearly 100 locations throughout Florida. Prior to his role as COO of FCS in 2011, Mr. Schonherz was Senior Vice President and Chief Information Officer for US Oncology. As part of the senior management team, Mr. Schonherz helped set organizational goals and objectives, oversaw strategic project prioritization, and led tactical execution of company-wide initiatives. He was also responsible for all day-to-day operational aspects of information technology and strategic direction for the information technology needs of the organization. While Senior Vice President and Chief Information Officer, he was named to the Information Week 500 and received the ComputerWorld/IDG Laureate Award, recognizing individuals and organizations that use information technology to benefit society. During his tenure at US Oncology, he also held positions as the Director of Enterprise Applications and Vice President of Information Systems. His consulting and management experience in healthcare information technology includes positions with Datamedic Corporation (acquired by VitalWorks and later Amicas Corporation), Multum Corporation (acquired by Cerner Corporation), and MedE America (acquired by WebMD and later HLTH Corporation). 

Mr. Schonherz received a bachelor’s degree in health policy and administration from Pennsylvania State University. He has presented at national industry conferences including multiple Community Oncology Alliance (COA) conferences as well as national and regional information technology conferences.

Dr. Shah is Associate Faculty at Harvard School of Public Health and Brigham Health and Managing Partner at WTM Advisors.  Previously, he held strategic leadership roles in biopharma focused on oncology and led the Value Based Care practice at Harvard Business School.  

He consults and speaks worldwide on Value Based Care, Technology-Enabled Health Care Delivery, and how through public-private partnerships, we can deliver a more accessible, affordable, and meaningful health care.  

Dr. Shah is an angel investor and serves as a consultant to academic medical centers, strategy consulting firms, biopharma, and the World Economic Forum.

Adria Warren is a healthcare lawyer with the Boston office of the law firm of Foley & Lardner. Ms. Warren advises hospitals, providers, and health care enterprises on complex transactions, corporate, and regulatory compliance matters. Her experience includes mergers, acquisitions, joint ventures, and other affiliations and strategic transactions; forming provider groups, networks, and alliances; and advising on fraud and abuse and HIPAA compliance, employment, reporting and disclosure requirements, and marketing compliance. She is a member of the firm’s Health Care and Technology Industry Teams.  

Ms. Warren brings a wealth of business and transactional experience to assist clients in the health care industry, including providers, medical device companies, life sciences companies, and health care information technology companies. In addition, Ms. Warren counsels entrepreneurs and established companies on a wide range of day-to-day legal and business issues from starting-up through going public, including corporate governance issues, securities laws compliance, tax, and employment matters.

Robin Zon, M.D., FACP, FASCO, worked in pharmaceutical research and manager of medical diagnostic product R&D prior to medical school. Dr. Zon earned her MD from Indiana University School of Medicine, completed residency at St. Vincent Hospital HCC in Indianapolis, and a fellowship at Indiana University Cancer Center. Dr. Zon served as Medical Director of Research at Memorial Hospital and NCI CCOP Associate/ Principal Investigator until 2013 for Indiana's only NCI designated Community Cancer Oncology Program. She has published over 80 articles, many as first or senior author and is a volunteer leader for ASCO, serving as past Chair of Government Relations, Chair of the Clinical Practice, the Board of Directors from 2010 to 2013, Chair of the Pathways Taskforce, Chair of the Oncology Practice Conference, Co-chair of the Telemedicine Expert Panel, along with many other ASCO related responsibilities. Dr. Zon served as past President of Michiana Hematology Oncology, currently Physician Emeritus. Additional activities included Vice-Chair of the Hoosier Cancer Research Group, Board member of RiverBend Cancer Services and the local Hospice. Currently Dr. Zon Chairs the South Bend Medical Foundation, is on the  Board for CancerLinQ and serves Women Who Conquer Cancer. Dr. Zon has received the ASCO Distinguished Achievement Award, ASCO’s National Advocate of the Year Award and multiple Advocacy President’s Circle; she has been called upon by the IOM, the NCI, the NAS and MASCC, to provide guidance and share her expertise. Dr. Zon meets local federal government elected officials routinely to promote cancer care policies.